Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Tanja %C5%A0pani%C4%87) .

1 - 10 / 379
First pagePrevious page12345678910Next pageLast page
1.
Febrile neutropenia in chemotherapy treated small-cell lung cancer patients
Renata Režonja, Iztok Grabnar, Tomaž Vovk, Aleš Mrhar, Viljem Kovač, Tanja Čufer, 2015, original scientific article

Abstract: Chemotherapy with platinum agent and etoposide for small-cell lung cancer (SCLC) is supposed to be associated with intermediate risk (10-20%) of febrileneutropenia. Primary prophylaxis with granulocyte colonystimulating factors (G-CSFs) is not routinely recommended by the treatment guidelines. However, in clinical practice febrile neutropenia is often observed with standard etoposide/platinum regimen. The aim of this analysis was to evaluate the frequency of neutropenia and febrile neutropenia in advanced SCLC patients in the first cycle of standard chemotherapy. Furthermore, we explored the association between severe neutropenia and etoposide peak plasma levels inthe same patients. The case series based analysis of 17 patients with advanced SCLC treated with standard platinum/etoposide chemotherapy, already included in the pharmacokinetics study with etoposide, was performed. Grade 3/4 neutropenia and febrile neutropenia, observed after the first cycle are reported. The neutrophil counts were determined on day one of the second cycle unless symptoms potentially related to neutropenia occurred. Adverse events were classified according to Common Toxicity Criteria 4.0. Additionally, association between severe neutropenia and etoposide peak plasma concentrations, which were measured in the scope of pharmacokinetic study, was explored. Two out of 17 patients received primary GCS-F prophylaxis. In 15 patient who did not receive primary prophylaxis the rates of both grade 3/4 neutropenia and febrile neutropenia were high (8/15 (53.3%) and 2/15 (13.3%), respectively), already in the first cycle of chemotherapy. One patient died due to febrile neutropenia related pneumonia. Neutropenic events are assumed to be related to increased etoposide plasma concentrations after a standard etoposide and cisplatin dose. While the mean etoposide peak plasma concentration in the first cycle of chemotherapy was 17.6 mg/l, the highest levels of 27.07 and 27.49 mg/l were determined in two patients with febrile neutropenia. Our study indicates that there is a need to reduce the risk of neutropenic events in chemotherapy treated advanced SCLC, starting in the first cycle. Mandatory use of primary G-CSF prophylaxis might be considered. Alternatively, use of improved risk models for identification of patients with increased risk for neutropenia and individualization of primary prophylaxis based on not only clinical characteristics but also on etoposide plasma concentration measurement, could be a new, promising options that deserves further evaluation.
Keywords: small cell lung cancer, platinum-etoposide chemotherapy, etoposide, febrile neutropenia, plasma drug concentration
Published in DiRROS: 22.04.2024; Views: 16; Downloads: 5
.pdf Full text (568,43 KB)
This document has many files! More...

2.
Zdravljenje IDH1 astrocitoma : prikaz primera
Blaž Tomič, Tanja Mesti, 2024, published professional conference contribution

Keywords: internistična onkologija, astrocitom, kemoterapija
Published in DiRROS: 22.04.2024; Views: 13; Downloads: 2
.pdf Full text (821,57 KB)

3.
Mosunetuzumab v monoterapiji pri refraktarnem folikularnem limfomu : klinični primer
Kristina Levpušček, Tanja Južnič Šetina, Milica Miljković, 2024, published professional conference contribution

Keywords: internistična onkologija, limfom, kemoterapija
Published in DiRROS: 22.04.2024; Views: 16; Downloads: 3
.pdf Full text (771,29 KB)

4.
Zdravljenje bolnice z metastatskim urotelnim karcinomom ledvičnega meha s sodobnimi onkološkimi zdravili
Mićo Božić, Tanja Ovčariček, 2024, published professional conference contribution

Keywords: internistična onkologija, rak ledvic, kemoterapija
Published in DiRROS: 22.04.2024; Views: 14; Downloads: 3
.pdf Full text (735,88 KB)

5.
Konjugat protitelo-zdravilo trastuzumab-derukstekan pri zdravljenju HER2-pozitivnega rak želodca
Lucija Bogdan, Tanja Mesti, 2024, published professional conference contribution

Keywords: internistična onkologija, rak želodca, kemoterapija
Published in DiRROS: 22.04.2024; Views: 15; Downloads: 5
.pdf Full text (864,86 KB)

6.
Mutacije IDH : nova terapevtska tarča za zdravljenje tumorjev prebavil in možganskih tumorjev
Tanja Mesti, 2024, published professional conference contribution

Keywords: internistična onkologija, rak prebavil, rak možganskih tumorjev
Published in DiRROS: 19.04.2024; Views: 63; Downloads: 14
.pdf Full text (817,06 KB)

7.
LAG-3 - nova terapevtska tarča za zdravljenje tumorjev prebavil
Tanja Mesti, 2024, published professional conference contribution

Keywords: internistična onkologija, rak prebavil, imunoterapija
Published in DiRROS: 19.04.2024; Views: 55; Downloads: 13
.pdf Full text (819,97 KB)

8.
Konjugati protitelo-zdravilo za zdravljenje raka dojk
Tanja Ovčariček, Erika Matos, 2024, published professional conference contribution

Keywords: internistična onkologija, rak dojke, kemoterapija
Published in DiRROS: 19.04.2024; Views: 38; Downloads: 10
.pdf Full text (818,60 KB)

9.
Cepiva za zdravljenje raka trebušne slinavke
Tanja Mesti, 2024, published professional conference contribution

Keywords: internistična onkologija, rak trebušne slinavke, cepiva
Published in DiRROS: 19.04.2024; Views: 44; Downloads: 10
.pdf Full text (744,40 KB)

10.
How beech provenance affects the structure of secondary xylem, leaf traits, and the ectomycorrhizal community under optimal growth conditions
Tanja Mrak, Jožica Gričar, Tina Unuk Nahberger, Gregor Božič, Luka Krajnc, Peter Prislan, Domen Arnič, Tom Levanič, Hojka Kraigher, 2024, original scientific article

Abstract: Beyond growth parameters and drought tolerance, comparatively little is known about the functioning of different beech (Fagus sylvatica L.) provenances. We investigated properties of leaves, stem secondary xylem, and ectomycorrhiza (ECM), and explored their interdependencies to identify the best performing beech provenance in optimal growth conditions. The study was conducted on 23-year-old trees in a provenance trial. The investigated provenances originated from Atlantic (Belgium—BE), Alpine (Italy—IT, Slovenia—SI), and continental climates (the Czech Republic—CZ). A significant effect of provenance was observed for stem vessel diameters and conductive area, as well as for foliar %C, δ13C, δ15N, and δ18O. δ13C as a proxy of intrinsic water use efficiency (iWUE) showed that the highest iWUE was achieved in BE provenance. Individuals with a better iWUE had wider growth rings regardless of provenance. Better iWUE was associated with lower specific leaf area (SLA). ECM community composition and diversity indices did not differ significantly among the provenances. Specific ECM taxa were associated with individuals with high SLA, δ13C, δ15N, and δ18O. In optimal growth conditions with no stress events, BE is a promising provenance due to an efficient water conducting system with high vessel diameters and conductive area, and high iWUE, while Alpine provenances showed an adaptation of their water conducting system to freezing conditions at their original locations. Integrating findings from different compartments improves our understanding of functioning of different beech provenances.
Keywords: Fagus sylvatica, provenance trial, stable isotopes, specific leaf area, xylem vessels, ectomycorrhizal fungi
Published in DiRROS: 19.04.2024; Views: 51; Downloads: 21
.pdf Full text (2,11 MB)
This document has many files! More...

Search done in 0.4 sec.
Back to top